Eli Lilly Will Sell Zepbound Through Telehealth Company Ro

Eli Lilly Will Sell Zepbound Through Telehealth Company Ro in a Swipe at Legal Copycats
Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the branded drugs, Lilly on Wednesday said it would sell a version of Zepbound through the telemedicine company Ro.
What can't weight-loss meds do? Eli Lilly is going to test Zepbound as a treatment for addiction
Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster drug as a treatment for alcohol and drug addiction starting next year.
Eli Lilly taps Ro to help it sell a cheaper version of its weight-loss drug
Eli Lilly is partnering with the Flatiron-based telehealth company Ro to sell a cheaper version of its popular weight-loss drug directly to patients.
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, according results of the study released Wednesday.
Ro, Eli Lilly to streamline patient access to Zepbound single-dose vials
Ro announced earlier that it is working with Eli Lilly (LLY) and Company to streamline access to Zepbound single-dose vials for Ro patients
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Lilly to offer single-dose vials of weight-loss drug on telehealth platform Ro
By Sneha S K (Reuters) -Telehealth company Ro said on Wednesday it will offer single-dose vials of Eli Lilly's weight-loss drug Zepbound to patients with obesity, becoming the first alternative platform for the lower-cost version of the drug to Lilly's own website.
Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
It is made possible through a first-of-a-kind integration with Eli Lilly's direct-to-consumer website, and aims to streamline access to the popular treatment.
Eli Lilly Stock Could Have a Huge Growth Catalyst in Early 2025
Eli Lilly ( LLY -0.44%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its ...
STAT21h
Eli Lilly strikes Zepbound deal with Ro, amid questions about future of compounded GLP-1s
Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.
Eli Lilly is partnering with Ro to make it easier than ever to get Zepbound
Eli Lilly (LLY) has announced it will make lower-priced, single-dose vials of its popular weight-loss treatment Zepound ...